Ruqin Chen

1.1k total citations
22 papers, 764 citations indexed

About

Ruqin Chen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ruqin Chen has authored 22 papers receiving a total of 764 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 3 papers in Surgery. Recurrent topics in Ruqin Chen's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Ruqin Chen is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Ruqin Chen collaborates with scholars based in United States, Spain and India. Ruqin Chen's co-authors include Coleman K. Obasaju, Joseph Treat, Yanyan Lou, Rami Manochakian, Kexun Zhou, Shi H, Yujie Zhao, Jane Bromund, Abdel‐Ghani Azzouqa and Yan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Critical Care Medicine.

In The Last Decade

Ruqin Chen

18 papers receiving 750 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruqin Chen United States	11	559	511	161	88	50	22	764
Naoki Furuya Japan	16	590 1.1×	510 1.0×	181 1.1×	126 1.4×	72 1.4×	89	827
Kei Takamura Japan	12	561 1.0×	453 0.9×	180 1.1×	107 1.2×	36 0.7×	40	773
Kentaro Ito Japan	14	473 0.8×	400 0.8×	213 1.3×	112 1.3×	44 0.9×	66	699
Giovanni Palazzolo Italy	15	474 0.8×	528 1.0×	211 1.3×	85 1.0×	42 0.8×	47	786
R. Lamy France	11	425 0.8×	500 1.0×	124 0.8×	142 1.6×	34 0.7×	32	633
Caicun Zhou China	12	393 0.7×	435 0.9×	197 1.2×	106 1.2×	30 0.6×	36	710
Kiichiro Ninomiya Japan	16	474 0.8×	512 1.0×	138 0.9×	67 0.8×	40 0.8×	81	715
Ivana Sullivan Spain	14	322 0.6×	509 1.0×	218 1.4×	100 1.1×	47 0.9×	55	686
L Portalone Italy	11	427 0.8×	418 0.8×	156 1.0×	84 1.0×	73 1.5×	26	668
J.M. Sánchez-Torres Spain	13	428 0.8×	614 1.2×	150 0.9×	104 1.2×	43 0.9×	21	772

Countries citing papers authored by Ruqin Chen

Since Specialization

Citations

This map shows the geographic impact of Ruqin Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruqin Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruqin Chen more than expected).

Fields of papers citing papers by Ruqin Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruqin Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruqin Chen. The network helps show where Ruqin Chen may publish in the future.

Co-authorship network of co-authors of Ruqin Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Ruqin Chen. A scholar is included among the top collaborators of Ruqin Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruqin Chen. Ruqin Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Ruqin, et al.. (2025). Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges. PubMed. 4(1). e000566–e000566.

Manochakian, Rami, et al.. (2024). Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy. Frontiers in Oncology. 14. 1306311–1306311.

Markovic, Svetomir N., Robert R. McWilliams, Lisa A. Kottschade, et al.. (2024). Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting. Melanoma Research. 34(6). 510–518.

Moustafa, Muhamad Alhaj, et al.. (2023). Brief report: risk stratification following curative therapy for stage I NSCLC. Frontiers in Oncology. 13. 1250315–1250315.

H, Shi, Karan Seegobin, Kexun Zhou, et al.. (2022). Genomic landscape of lung adenocarcinomas in different races. Frontiers in Oncology. 12. 946625–946625. 26 indexed citations

Zhou, Kexun, Shi H, Ruqin Chen, et al.. (2021). Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Network Open. 4(1). e2032276–e2032276. 31 indexed citations

Azzouqa, Abdel‐Ghani, Ruqin Chen, Yanyan Lou, Sikander Ailawadhi, & Rami Manochakian. (2019). Impact of time to treatment initiation (TTI) on survival of patients with newly diagnosed non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). 9058–9058. 5 indexed citations

Chen, Ruqin, et al.. (2017). Gamma-delta (γδ) T-cell lymphoma – another case unclassifiable by World Health Organization classification: a case report. Journal of Medical Case Reports. 11(1). 163–163. 5 indexed citations

Obasaju, Coleman K., Rafat Ansari, Mark A. Socinski, et al.. (2010). A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(7). 993–1000. 7 indexed citations

10.

Edelman, Martin J., Chandra P. Belani, Mark A. Socinski, et al.. (2010). Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(1). 110–116. 27 indexed citations

11.

Ansari, Rafat, Mark A. Socinski, Martin J. Edelman, et al.. (2010). A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology. 78(2). 162–171. 33 indexed citations

12.

Treat, Joseph, Martin J. Edelman, Chandra P. Belani, et al.. (2010). A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer. 70(3). 340–346. 15 indexed citations

13.

Dudek, Arkadiusz Z., Timothy Larson, Michael McCleod, et al.. (2008). Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(4). 394–399. 16 indexed citations

14.

Kulkarni, Pandurang M., Ruqin Chen, Taruna Anand, Matthew Monberg, & Coleman K. Obasaju. (2008). Efficacy and safety of pemetrexed in elderly cancer patients: Results of an integrated analysis. Critical Reviews in Oncology/Hematology. 67(1). 64–70. 7 indexed citations

15.

Socinski, Mark A., Robert N. Raju, Marcus A. Neubauer, et al.. (2008). Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial. Journal of Thoracic Oncology. 3(11). 1308–1316. 20 indexed citations

16.

Fidias, Panos, Shaker R. Dakhil, Alan P. Lyss, et al.. (2008). Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(4). 591–598. 304 indexed citations

17.

Socinski, Mark A., Robert N. Raju, Donald Richards, et al.. (2007). P1-229: The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small-cell lung cancer (SCLC). Journal of Thoracic Oncology. 2(8). S829–S830. 1 indexed citations

18.

Treat, Joseph, Philip Bonomi, Michael McCleod, et al.. (2006). Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A phase II trial. Lung Cancer. 53(1). 77–83. 17 indexed citations

19.

Levy, Howard, David S. Small, Darell Heiselman, et al.. (2005). Obesity Does Not Alter the Pharmacokinetics of Drotrecogin Alfa (Activated) in Severe Sepsis. Annals of Pharmacotherapy. 39(2). 262–267. 16 indexed citations

20.

Safcsak, Karen, Michael L. Cheatham, Jay S. Steingrub, et al.. (2004). SURGICAL/TRAUMA PATIENTS RECEIVING DROTRECOGIN ALFA (ACTIVATED) IN CLINICAL PRACTICE HAVE OUTCOMES SIMILAR TO PATIENTS IN PROWESS. Critical Care Medicine. 32(Supplement). A145–A145. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact